Compare ASTI & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | CRVO |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8M | 47.7M |
| IPO Year | 2014 | 2011 |
| Metric | ASTI | CRVO |
|---|---|---|
| Price | $6.68 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | ★ 2.6M | 88.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,398,149.00 | $9,737,974.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 163.25 | 36.29 |
| 52 Week Low | $1.17 | $1.92 |
| 52 Week High | $9.87 | $16.50 |
| Indicator | ASTI | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 31.30 |
| Support Level | $1.65 | N/A |
| Resistance Level | $8.44 | $5.44 |
| Average True Range (ATR) | 1.16 | 0.44 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 31.78 | 15.74 |
Ascent Solar Technologies Inc is engaged in the manufacturing, and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.